UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (1) FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3831168 (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K Title of each class Trading Symbol Name of each exchange on which registered Common Stock $0.001 par value per share ACOR Nasdaq Global Select Market Securities registered pursuant to Section 12(g) of the Act: None ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE AC ...

PEARL RIVER, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced it will regain global commercialization rights to FAMPYRA® (fampridine) following a decision by Biogen to terminate the license and collaboration agreement between the companies, effective January 1, 2025. FAMPYRA is indicated in the European Union and other territories throughout the world for the improvement of walking in adults with multiple sclerosis (MS) with walking disability. Acorda markets the medication as ...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Conference Call November 13, 2023 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO Conference Call Participants Operator Welcome to Acorda Therapeutics Third Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is bei ...

CONTACT: Tierney Saccavino (914) 326-5104 tsaccavino@acorda.com FOR IMMEDIATE RELEASE Acorda Therapeutics Reports Third Quarter 2023 Financial Results • INBRIJA® (levodopa inhalation powder) Q3 2023 U.S. net revenue of $8.1 million; 4% increase over Q3 2022 • AMPYRA® (dalfampridine) Q3 2023 net revenue of $15.7 million; 26% decrease over Q3 2022 • INBRIJA ex-U.S. revenue of $1.4 million; FAMPYRA royalties of $2.5 million • Biopas Laboratories files for approval of INBRIJA in six Latin American countries PEA ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3831168 (State or other jurisdiction ...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO Conference Call Participants Operator Welcome to Acorda Therapeutics Second Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode. There will be a question-and-answer session to follow. Please be advised that this call is being ...

we UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3831168 (State or other jurisdiction o ...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Tierney Saccavino - EVP, Corporate Communications Ron Cohen - Founder, CEO, President & Director Michael Gesser - CFO Conference Call Participants Operator Welcome to Acorda Therapeutics First Quarter 2023 Financial and Business Update. [Operator Instructions]. Please be advised that this call is being recorded at the company's request. I will now introduce your host for today's call, Tierne ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-31938 ACORDA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 13-3831168 (State or other jurisdiction of ...